|
Authors | Study design | Participants | Treatment duration | Celecoxib doses | Antipsychotics | Major findings |
|
Müller et al. 2002 [108] | Double-blind, randomized, placebo-controlled, add-on | Schizophrenics Duration of illness not specified (mean 5.9 years) | 5 weeks | 400 mg/day | Risperidone (flexible dose) | Significant advantage of the COX-2 inhibitor |
|
Rappart and Müller 2004 [109] | Double-blind, randomized, placebo-controlled, add-on | Schizophrenics Duration of illness ≤10 years | 11 weeks | 400 mg/day | Risperidone (flexible dose) | No advantage on the COX-2 inhibitor |
|
Rapaport et al. 2005 [110] | Double-blind, randomized, placebo-controlled, add-on | Schizophrenics Continuously ill (mean 20 years) | 8 weeks | 400 mg/day | Risperidone or olanzapine (constant dose) | No advantage on the COX-2 inhibitor |
|
Zhang et al. 2006 [111] | Double-blind, randomized, placebo-controlled, add-on | First manifestation schizophrenia | 12 weeks | 400 mg/day | Risperidone (flexible dose) | Significant advantage of the COX-2 inhibitor |
|
Akhondzadeh et al. 2007 [112] | Double-blind, randomized, placebo-controlled, add-on | Active phase of chronic schizophrenia | 8 weeks | 400 mg/day | Risperidone (flexible dose) | Significant advantage of the COX-2 inhibitor |
|
Müller et al. 2010 [113] | Double-blind, randomized, placebo-controlled, add-on | First manifestation schizophrenia | 6 weeks | 400 mg/day | Amisulpride (flexible dose) | Significant advantage of the COX-2 inhibitor |
|